{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:21:43Z","timestamp":1756902103492,"version":"3.44.0"},"reference-count":49,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:p>Infection due to <jats:italic>Shigella<\/jats:italic> species remains an important public health problem, especially in developing countries where it remains the most common cause of bloody diarrhea. In the United States (US), 10,000 to 15,000 cases of shigellosis are reported each year in both children and adults. US surveillance data from 2004 has demonstrated increased resistance in <jats:italic>Shigella<\/jats:italic> species to first-line antibiotics such as ampicillin and trimethoprim-sulfamethoxazole, with approximately 37% of isolates demonstrating resistance to both ampicillin and trimethoprim-sulfamethoxazole. Since approximately 69% of <jats:italic>Shigella<\/jats:italic> infections occur in children younger than 5 years of age, it is important that alternative antibiotics other than typical first-line agents such as ampicillin and trimethoprim-sulfamethoxazole be available to treat <jats:italic>Shigella<\/jats:italic> infections in this population. The American Academy of Pediatrics (AAP) recommends cefixime, ceftriaxone, azithromycin, and fluoroquinolones as alternative antibiotics for the treatment of <jats:italic>Shigella<\/jats:italic> species infections in children. This paper will review the microbiology, susceptibility, efficacy and safety data of these alternative antibiotics with regard to the treatment of <jats:italic>Shigella<\/jats:italic> species infections in children, and will attempt to define the role of each of these agents in the pediatric population.<\/jats:p>","DOI":"10.5863\/1551-6776-13.1.29","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T20:09:33Z","timestamp":1603829373000},"page":"29-43","source":"Crossref","is-referenced-by-count":4,"title":["Options for Treating Resistant Shigella Species Infections in Children"],"prefix":"10.5863","volume":"13","author":[{"given":"Sharon M.","family":"Erdman","sequence":"first","affiliation":[{"name":"Purdue University School of Pharmacy, Department of Pharmacy Practice, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth E.","family":"Buckner","sequence":"additional","affiliation":[{"name":"Target Pharmacy, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet F.","family":"Hindler","sequence":"additional","affiliation":[{"name":"UCLA Medical Center, Department of Clinical Microbiology, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"year":"2005","series-title":"Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1","key":"i1551-6776-13-1-29-b1","unstructured":"World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. Geneva, Switzerland: World Health Organization Press; 2005."},{"key":"i1551-6776-13-1-29-b2","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"1","article-title":"Summary of notifiable diseases \u2013 United States, 2004","volume":"53","year":"2006","unstructured":"Centers for Disease Control and Prevention. Summary of notifiable diseases \u2013 United States, 2004. MMWR Morb Mortal Wkly Rep2006;53:1\u201379."},{"key":"i1551-6776-13-1-29-b3","series-title":"Gastroenterol Clin North Am","first-page":"817","article-title":"The role of antibiotics in the treatment of infectious diarrhea","volume":"30","year":"2001","unstructured":"Oldfield\n              EC\n            , WallaceMR.\n          The role of antibiotics in the treatment of infectious diarrhea. Gastroenterol Clin North Am2001;30:817\u201336."},{"key":"i1551-6776-13-1-29-b4","series-title":"J Microbiol","first-page":"133","article-title":"Shigellosis","volume":"43","year":"2005","unstructured":"Niyogi\n              SK.\n            \n          \n          Shigellosis. J Microbiol2005;43:133\u2013143."},{"article-title":"Section 3: Summaries of Infectious Diseases: Shigella Infections","series-title":"Red Book: 2006 Report of the Committee on Infectious Diseases","key":"i1551-6776-13-1-29-b5","unstructured":"American Academy of Pediatrics Committee on Infectious Diseases. Section 3: Summaries of Infectious Diseases: Shigella Infections. In: Red Book: 2006 Report of the Committee on Infectious Diseases, 27th Edition. Accessed online via StatRef on December 6, 2006."},{"key":"i1551-6776-13-1-29-b6","series-title":"Paediatr Drugs","first-page":"279","article-title":"Acute gastroenteritis in children: What role for antibacterials?","volume":"5","year":"2003","unstructured":"Phavichitr\n              N\n            , Catto-SmithA.\n          Acute gastroenteritis in children: What role for antibacterials?\n          Paediatr Drugs\n          2003;5:279\u2013290."},{"year":"2007","series-title":"National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2004","key":"i1551-6776-13-1-29-b7","unstructured":"Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2004. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2007."},{"key":"i1551-6776-13-1-29-b8","series-title":"Antimicrob Agents Chemother","first-page":"415","article-title":"Comparative efficacy of cephalexin and ampicillin for shigellosis and other types of acute diarrhea in infants and children","volume":"7","year":"1975","unstructured":"Nelson\n              JD\n            , HaltalinKC.\n          Comparative efficacy of cephalexin and ampicillin for shigellosis and other types of acute diarrhea in infants and children. Antimicrob Agents Chemother1975;7:415\u201320."},{"key":"i1551-6776-13-1-29-b9","series-title":"Chemotherapy","first-page":"40","article-title":"In vitro effectiveness of four cephalosporins against shigellae and clinical ineffectiveness of cephaloglycan","volume":"17","year":"1972","unstructured":"Nelson\n              JD\n            , HaltalinKC.\n          In vitro effectiveness of four cephalosporins against shigellae and clinical ineffectiveness of cephaloglycan. Chemotherapy1972;17:40\u201360."},{"key":"i1551-6776-13-1-29-b10","series-title":"Am J Med Sci","first-page":"27","article-title":"Antibiotic treatment of acute shigellosis: Failure of cefamandole compared with trimethoprim\/sulfamethoxazole and ampicillin","volume":"282","year":"1981","unstructured":"Orenstein\n              WA\n            , RossL, OverturfGD, et al. Antibiotic treatment of acute shigellosis: Failure of cefamandole compared with trimethoprim\/sulfamethoxazole and ampicillin. Am J Med Sci1981;282:27\u201333."},{"key":"i1551-6776-13-1-29-b11","series-title":"Pediatr Infect Dis J","first-page":"644","article-title":"Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease","volume":"11","year":"1992","unstructured":"Prado\n              D\n            , LopezE, LiuH, et al. Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease. Pediatr Infect Dis J1992;11:644\u2013647."},{"key":"i1551-6776-13-1-29-b12","first-page":"98","article-title":"Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement, M100-S18, Wayne, PA","volume":"27","year":"January 2008","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement, M100-S18, Wayne, PA. January 2008; 27: 98\u2013101."},{"key":"i1551-6776-13-1-29-b13","series-title":"J Pediatr","first-page":"817","article-title":"A randomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis","volume":"123","year":"1993","unstructured":"Ashkenazi\n              S\n            , AmirJ, WaismanY, et al. A randomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis. J Pediatr1993;123:817\u2013821."},{"key":"i1551-6776-13-1-29-b14","series-title":"Pediatr Infect Dis J","first-page":"374","article-title":"Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children","volume":"22","year":"2003","unstructured":"Basualdo\n              W\n            , ArboA.\n          Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J2003;22:374\u2013377."},{"key":"i1551-6776-13-1-29-b15","series-title":"Ann Intern Med","first-page":"505","article-title":"Treatment of shigellosis: IV. Cefixime is ineffective in shigellosis in adults","volume":"123","year":"1995","unstructured":"Salam\n              MA\n            , SeasC, KhanWA, et al. Treatment of shigellosis: IV. Cefixime is ineffective in shigellosis in adults. Ann Intern Med1995;123:505\u2013508."},{"key":"i1551-6776-13-1-29-b16","series-title":"Pediatr Infect Dis J","first-page":"1060","article-title":"Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children","volume":"19","year":"2000","unstructured":"Leibovitz\n              E\n            , JancoJ, PiglanskyL, et al. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J2000;19:1060\u20131067."},{"key":"i1551-6776-13-1-29-b17","series-title":"J Pediatr","first-page":"627","article-title":"Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children","volume":"118","year":"1991","unstructured":"Varsano\n              I\n            , Eidlitz-MarcusT, NussinovitchM, et al. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr1991;118:627\u2013632."},{"key":"i1551-6776-13-1-29-b18","series-title":"Drugs Exp Clin Res","first-page":"613","article-title":"In vitro activity of azithromycin (CP-62,993), a novel macrolide, against enteric pathogens","volume":"14","year":"1988","unstructured":"Jones\n              K\n            , FelminghamD, RidgwayG.\n          In vitro activity of azithromycin (CP-62,993), a novel macrolide, against enteric pathogens. Drugs Exp Clin Res1988;14:613\u2013615."},{"key":"i1551-6776-13-1-29-b19","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"541","article-title":"Comparative in vitro activity of the new oral macrolide azithromycin","volume":"7","year":"1988","unstructured":"Neu\n              HC\n            , ChinNX, SahaG, et al. Comparative in vitro activity of the new oral macrolide azithromycin. Eur J Clin Microbiol Infect Dis1988;7:541\u2013544."},{"key":"i1551-6776-13-1-29-b20","series-title":"Antimicrob Agents Chemother","first-page":"277","article-title":"In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanisms of delivery and release at sites of infection","volume":"33","year":"1989","unstructured":"Gladue\n              RP\n            , BrightGM, IsaacsonRE, et al. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanisms of delivery and release at sites of infection. Antimicrob Agents Chemother1989;33:277\u2013282."},{"key":"i1551-6776-13-1-29-b21","series-title":"Ann Intern Med","first-page":"697","article-title":"Treatment of shigellosis: comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial","volume":"126","year":"1997","unstructured":"Khan\n              WA\n            , SeasC, DharU, et al. Treatment of shigellosis: comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial. Ann Intern Med1997;126:697\u2013703."},{"key":"i1551-6776-13-1-29-b22","series-title":"Pediatr Infect Dis J","first-page":"494","article-title":"Antimicrobial-resistant Shigella sonnei: Limited antimicrobial treatment options for children and challenges of interpreting in vitro azithromycin susceptibility","volume":"24","year":"2005","unstructured":"Jain\n              SK\n            , GuptaA, GlanzB, et al. Antimicrobial-resistant Shigella sonnei: Limited antimicrobial treatment options for children and challenges of interpreting in vitro azithromycin susceptibility. Pediatr Infect Dis J2005;24:494\u2013497."},{"key":"i1551-6776-13-1-29-b23","series-title":"Antimicrob Agents Chemother","first-page":"1203","article-title":"In vitro activity of azithromycin against bacterial enteric pathogens","volume":"37","year":"1993","unstructured":"Gordillo\n              ME\n            , SinghKV, MurrayBE.\n          In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother1993;37:1203\u20131205."},{"key":"i1551-6776-13-1-29-b24","series-title":"Diagn Microbiol Infect Dis","first-page":"187","article-title":"Natural antibiotic susceptibility of Escherichia coli, Shigella, E. vulneris, and E. hermannii strains","volume":"33","year":"1999","unstructured":"Stock\n              I\n            , WiedemannB.\n          Natural antibiotic susceptibility of Escherichia coli, Shigella, E. vulneris, and E. hermannii strains. Diagn Microbiol Infect Dis1999;33:187\u2013199."},{"issue":"Supp 2","key":"i1551-6776-13-1-29-b25","series-title":"Drugs","first-page":"43","article-title":"Fluoroquinolones in paediatrics","volume":"58","year":"1999","unstructured":"Jafri\n              HS\n            , McCrackenGHJr.\n          Fluoroquinolones in paediatrics. Drugs1999;58(Supp 2):43\u201348."},{"key":"i1551-6776-13-1-29-b26","series-title":"Pediatr Infect Dis J","first-page":"1128","article-title":"Safety profile of quinolone antibiotics in the pediatric population","volume":"22","year":"2003","unstructured":"Grady\n              R.\n            \n          \n          Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J2003;22:1128\u20131132."},{"key":"i1551-6776-13-1-29-b27","series-title":"Clin Infect Dis","first-page":"1196","article-title":"Quinolone arthropathy in animals versus children","volume":"25","year":"1997","unstructured":"Burkhardt\n              JE\n            , WalterspielJN, SchaadUB.\n          Quinolone arthropathy in animals versus children. Clin Infect Dis1997;25:1196\u20131204."},{"issue":"Supp 5","key":"i1551-6776-13-1-29-b28","series-title":"Rev Infect Dis","first-page":"S1113","article-title":"Use of quinolones in pediatric patients","volume":"11","year":"1989","unstructured":"Adam\n              D.\n            \n          \n          Use of quinolones in pediatric patients. Rev Infect Dis1989;11(Supp 5):S1113\u20131116."},{"key":"i1551-6776-13-1-29-b29","series-title":"Infection","first-page":"289","article-title":"Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation","volume":"19","year":"1991","unstructured":"Chysky\n              V\n            , KapilaK, HullmannR, et al. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection1991;19:289\u2013296."},{"key":"i1551-6776-13-1-29-b30","series-title":"Acta Paediatr","first-page":"555","article-title":"Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth","volume":"84","year":"1995","unstructured":"Pradhan\n              KM\n            , AroraNK, JenaA, et al. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta Paediatr1995;84:555\u2013560."},{"key":"i1551-6776-13-1-29-b31","series-title":"Pediatr Infect Dis J","first-page":"572","article-title":"Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group","volume":"16","year":"1997","unstructured":"Richard\n              DA\n            , Nousia-ArvanitakisS, SollichV, et al. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatr Infect Dis J1997;16:572\u2013578."},{"key":"i1551-6776-13-1-29-b32","series-title":"Lancet","first-page":"522","article-title":"Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis","volume":"352","year":"1998","unstructured":"Salam\n              MA\n            , DharU, KhanWA, et al. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet1998;352:522\u2013527."},{"key":"i1551-6776-13-1-29-b33","series-title":"Pediatr Infect Dis J","first-page":"723","article-title":"Clinical, radiological and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin","volume":"10","year":"1991","unstructured":"Schaad\n              UB\n            , StoupisC, WedgwoodJ, et al. Clinical, radiological and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J1991;10:723\u2013729."},{"key":"i1551-6776-13-1-29-b34","series-title":"Infection","first-page":"165","article-title":"Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity","volume":"15","year":"1987","unstructured":"Schaad\n              UB\n            , Wedgwood-KruckoJ.\n          Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection1987;15:165\u2013168."},{"key":"i1551-6776-13-1-29-b35","series-title":"Clin Infect Dis","first-page":"470","article-title":"Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and\/or AOM treatment failure","volume":"41","year":"2005","unstructured":"Pichichero\n              ME\n            , ArguedasA, DaganR, et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and\/or AOM treatment failure. Clin Infect Dis2005;41:470\u2013478."},{"year":"December 2005","series-title":"Cipro (ciprofloxacin) prescribing information","key":"i1551-6776-13-1-29-b36","unstructured":"Bayer Pharmaceutical Corp. Cipro (ciprofloxacin) prescribing information. West Haven, CT, December 2005."},{"key":"i1551-6776-13-1-29-b37","series-title":"Pediatr Infect Dis J","first-page":"130","article-title":"Ciprofloxacin safety in a pediatric population","volume":"16","year":"1997","unstructured":"Jick\n              S.\n            \n          \n          Ciprofloxacin safety in a pediatric population. Pediatr Infect Dis J1997;16:130\u2013134."},{"key":"i1551-6776-13-1-29-b38","series-title":"Pediatr Infect Dis J","first-page":"127","article-title":"Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use \u2013 safety report","volume":"16","year":"1997","unstructured":"Hampel\n              B\n            , HullmannR, SchmidtH.\n          Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use \u2013 safety report. Pediatr Infect Dis J1997;16:127\u2013129."},{"key":"i1551-6776-13-1-29-b39","series-title":"Pediatr Infect Dis J","first-page":"525","article-title":"Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin","volume":"21","year":"2002","unstructured":"Yee\n              CL\n            , DuffyC, GerbinoPG, et al. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J2002;21:525\u2013529."},{"key":"i1551-6776-13-1-29-b40","unstructured":"Food and Drug Administration Talk Paper. Approval of Cipro for use after exposure to inhalational anthrax. Available at: http:\/\/www.fda.gov\/bbs\/topics\/ANSWERS\/ANS01030.html Accessed January 12, 2007.","article-title":"Approval of Cipro for use after exposure to inhalational anthrax"},{"article-title":"Section 4: Antimicrobial Agents and Related Therapy: Fluoroquinolones","series-title":"RedBook: 2006 Report of the Committee on Infectious Diseases","key":"i1551-6776-13-1-29-b41","unstructured":"American Academy of Pediatrics Committee on Infectious Diseases. Section 4: Antimicrobial Agents and Related Therapy: Fluoroquinolones. In: RedBook: 2006 Report of the Committee on Infectious Diseases, 27th Edition. Accessed online via StatRef on January 12, 2007."},{"key":"i1551-6776-13-1-29-b42","series-title":"Antimicrob Agents Chemother","first-page":"2486","article-title":"Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones","volume":"37","year":"1993","unstructured":"Horiuchi\n              S\n            , InagakiY, YamamotoN, et al. Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones. Antimicrob Agents Chemother1993;37:2486\u20132489."},{"key":"i1551-6776-13-1-29-b43","series-title":"Lancet","first-page":"785","article-title":"Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolones","volume":"361","year":"2003","unstructured":"Sarkar\n              K\n            , NiyogiSK, BhattacharyaSK.\n          Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolones. Lancet2003;361:785."},{"key":"i1551-6776-13-1-29-b44","series-title":"Antimicrob Agents Chemother","first-page":"1203","article-title":"Antimicrobial susceptibility of Shigella sonnei isolates in Japan and molecular analysis of S. sonnei strains with reduced susceptibility to fluoroquinolones","volume":"49","year":"2005","unstructured":"Hirose\n              K\n            , TerajimaJ, IzumiyaH, et al. Antimicrobial susceptibility of Shigella sonnei isolates in Japan and molecular analysis of S. sonnei strains with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother2005:49:1203\u20131205."},{"key":"i1551-6776-13-1-29-b45","series-title":"Lancet Infect Dis","first-page":"755","article-title":"Multidrug-resistant Shigella dysenteriae type 1 in south Asia","volume":"3","year":"2003","unstructured":"Bhattacharya\n              SK\n            , SarkarK, NairBG, et al. Multidrug-resistant Shigella dysenteriae type 1 in south Asia. Lancet Infect Dis2003;3:755."},{"key":"i1551-6776-13-1-29-b46","series-title":"Lancet Infect Dis","first-page":"607","article-title":"Fluoroquinolone-resistant Shigella dysenteriae type 1 in northeastern Bangladesh","volume":"4","year":"2004","unstructured":"Naheed\n              A\n            , KalluriP, TalukderKA, et al. Fluoroquinolone-resistant Shigella dysenteriae type 1 in northeastern Bangladesh. Lancet Infect Dis2004;4:607\u2013608."},{"key":"i1551-6776-13-1-29-b47","series-title":"Epidemiol Infect","first-page":"1089","article-title":"Species diversity and antimicrobial resistance of Shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhoea in Kolkata (Calcutta), India","volume":"133","year":"2005","unstructured":"Pazhani\n              GP\n            , RamamurthyT, MitraU, et al. Species diversity and antimicrobial resistance of Shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhoea in Kolkata (Calcutta), India. Epidemiol Infect2005;133:1089\u20131095."},{"key":"i1551-6776-13-1-29-b48","series-title":"Curr Microbiol","first-page":"108","article-title":"Fluoroquinolone resistance linked to both gyrA and parC mutations in the quinolone-resistance determining region of Shigella dysenteriae type 1","volume":"52","year":"2006","unstructured":"Talukder\n              KA\n            , KhajanchiBK, IslamM, et al. Fluoroquinolone resistance linked to both gyrA and parC mutations in the quinolone-resistance determining region of Shigella dysenteriae type 1. Curr Microbiol2006;52:108\u2013111."},{"key":"i1551-6776-13-1-29-b49","series-title":"Acta Paediatr","first-page":"319","article-title":"Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children","volume":"86","year":"1997","unstructured":"Bhattacharya\n              SK\n            , BhattacharyaMK, DuttaD, et al. Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr1997;86:319\u2013320."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/13\/1\/article-p29.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/13\/1\/29\/1783962\/1551-6776-13_1_29.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/13\/1\/article-p29.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/13\/1\/article-p29.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:45:25Z","timestamp":1747356325000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/13\/1\/article-p29.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":49,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-13.1.29","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}